Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to Humans

Journal of Pharmaceutical Sciences

Volumn 93, Issue 1, 2004, Pages 177-185

  Mahmood, Iftekhar ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Clearance; Interspecies scaling; Protein drugs; Two versus three species

Indexed keywords

ALTEPLASE; ATRIAL NATRIURETIC FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DIGOXIN ANTIBODY F(AB) FRAGMENT; ERYTHROPOIETIN; HIRUDIN; INTERLEUKIN 2 DERIVATIVE; LENERCEPT; MACROGOL DERIVATIVE; PROTEIN DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT RELAXIN; RETEPLASE; SARUPLASE; VASCULOTROPIN;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; BABOON; BODY WEIGHT; BRAIN WEIGHT; CONTROLLED STUDY; DATA ANALYSIS; DOG; DRUG CLEARANCE; EVALUATION; HUMAN; LIFESPAN; MACROMOLECULE; MONKEY; NONHUMAN; PREDICTION; RABBIT; RAT; RODENT;

EID: 0347755132     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10531     Document Type: Article

References (36)

1. Boxenbaum H, Dilea C. 1995. First-time-in-human dose selection: Allometric thoughts and perspectives. J Clin Pharmacol 35:957-966.
2. Mahmood I, Balian JD. 1996. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895.
3. Boxenbaum H, Fertig JB. 1984. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokin 9:177-183.
4. Lave TH, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo PH. 1997. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590.
5. Obach RS, Baxter JG, Liston TE, Silber BM, Jones C, Macintyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from pre-clinical and in vitro metabolism. J Pharmacol Exp Ther 283:46-58.
6. Mahmood I. 1998. Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
7. Mahmood I, Sahajwalla C. 2002. Interspecies scaling of biliary excreted drugs. J Pharm Sci 91:1908-1914.
8. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
9. Braeckman R. 2000. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid RE, editor. Peptide and protein drug analysis. New York: Marcel Dekker Inc., pp 633-669.
10. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. 1996. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 136:75-78.
11. Stokol T, Trepanier L, Parry BW, Finnin BC. 1997. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res Vet Sci 63:23-27.
12. Grene-Lerouge NAM, Bazin-Redurea MI, Debray M, Scherrmann JMG. 1996. Interspecies scaling of clearance and volume of distribution for digoxin-specific fab. Toxicol Appl Pharmacol 138:84-89.
13. Ujhelyi MR, Robert S. 1995. Pharmacokinetic aspects of digioxin-specific fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 28:483-493.
14. Bleul H, Hoffmann R, Kaufmann B, Neubert P, Ochlich P, Schaumann W. 1996. Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology 52:329-338.
15. Halstenson CE, Macres M, Katz AS, Schnieders JR, Watanabe M, Sobota JT, Abraham PA. 1991. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712.
16. Keith JC, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG. 1994. Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thromb Haemost 73:101-105.
17. McCarthy K, Stewart P, Sigman J, Read M, Keith JC, Brinkhous KM, Nichols TC, Schaub RG. 2002. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 87:824-830.
18. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, et al. 1998. Clinical evaluation of recombinant factor IX. Semin Hematol 35(suppl 2)33-38.
19. Soon WH, Park SJ, Kim IC, Lee MG. 1997. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mail Pathol Pharmacol 96:227-240.
20. Kato M, Okano K, Sakamoto Y, Milura K, Uchimura T, Saito K. 2001. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats. Arzneimittelforschschung 51:91-95.
21. Fu JS, Lertora JJ, Brookins J, Rice JC, Fisher JW. 1988. Pharmacokinetics of erythropoietin in intact and anephric dogs. J Lab Clin Med 111:669-676.
22. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. 1990. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557-564.
23. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378.
24. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. 2001. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850.
25. Martin U, Kohler J, Sponer G, Strein K. 1992. Pharmacokinetics of the Novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 6:39-43.
26. Martin U, Mollendorff EV, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. 1991. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 66:569-574.
27. Nowak G. 1991. Pharmacokinetics of Hirudin. Semin Thromb Hemost 15:293-301.
28. Krieter PA, Trapani AJ. 1989. Metabolism of atrial natriuretic peptide. Extraction by organs in the rat. Drug Metab Dispos 17:14-19.
29. Marleau S, Ong H, De Lean A, du Souich P. 1989. Disposition and dynamics of atrial natriuretic factor in conscious rabbits. J Pharmacol Exp Ther 251:328-333.
30. Cernacek P, Maher E, Crawhall JC, Levy M. 1988. Renal dose response and pharmacokinetics of atrial natriuretic factor in dogs. Am J Physiol 255(6 Pt 2): R929-R935.
31. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. 1986. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38:1827-1833.
32. Richter WF, Gallati H, Schiller CD. 1999. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 27:21-25.
33. Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. 1991. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasmonigen activators. Circulation 84:1216-1234.
34. Boer DA, Kluft C, Gerloff J, Dooijewaard G, Gunzler WA, Beier H, Meer VD, Cohen AF. 1993. Pharmacokinetics of Saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. Thromb Haemost 70:320-325.
35. Sacher G. 1959. Relation of lifespan to brain weight and body weight in mammals. In: Wolstenholme GEW, O'Connor M, editors. CIBA Foundation colloquia on aging. London: Churchill, pp 115-133.
36. Mahmood I, Balian JD. 1996. Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 59:579-585.